Research analysts at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO – Get Rating) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.
EKSO stock opened at $1.75 on Wednesday. Ekso Bionics has a 52 week low of $1.54 and a 52 week high of $5.88. The company has a quick ratio of 6.76, a current ratio of 7.22 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $2.03 and a two-hundred day simple moving average of $2.47. The firm has a market capitalization of $22.48 million, a P/E ratio of -2.01 and a beta of 1.96.
Ekso Bionics (NASDAQ:EKSO – Get Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.05. Ekso Bionics had a negative net margin of 90.01% and a negative return on equity of 33.87%. The business had revenue of $2.57 million during the quarter, compared to analyst estimates of $3.20 million. During the same quarter last year, the business earned ($0.34) earnings per share. As a group, analysts anticipate that Ekso Bionics will post -1 EPS for the current year.
Ekso Bionics Company Profile (Get Rating)
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Recommended Stories
- Get a free copy of the StockNews.com research report on Ekso Bionics (EKSO)
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.